Abstract
Knowledge-based interpretations are essential for understanding the omic data set because of its nature, such as high dimension and hidden biological information in genes. When analyzing gene expression data with many genes and few samples, the main problem is to separate disease-related information from a vast quantity of redundant data and noise. This paper uses a reliable framework to determine important genes for discovering Hepato-cellular Carcinoma (HCC) from micro-array analysis and eliminating redundant and unnecessary genes through gene selection. Several machine learning models were applied to find significant predictors responsible for HCC. As we know, classification algorithms such as Random Forest, Naive Bayes classifier, or a k-Nearest Neighbor classifier can help us to classify HCC from responsible genes. Random Forests shows 96.53% accuracy with p < 0.00001, which is better than other discussed Machine Learning(ML) approaches. Each gene is not responsible for a particular patient. Since ML approaches are like black boxes and people/practitioners do not rely on them sometimes. Artificial Intelligence(AI) technologies with high optimization interoperability shed light on what is happening inside these systems and aid in the detection of potential problems; including causality, information leakage, model bias, and robustness when determining responsible genes for a specific patient with a high probability score of almost 0.99, from one of the samples mentioned in this study.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no funding for this project
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study considered a published data set which was publicly available at the to reuse the data set for research purposes and scientific developments. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14520&fbclid=IwAR0iw_BN2d62NEyxHaQVhGBxSXgBcpiZcgipvBYcuzYzpwCTRPPZDG0NDsk
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
(email: mhasan8{at}miners.utep.edu)
(email:fahad.mostafa{at}ttu.edu)
(email: Md-Sakhawat.Hossain{at}ttu.edu)
(email: jonathonloftin{at}saumag.edu)
